Novo Nordisk is doing its bit to reverse the Danish brain drain, offering a number of “return” fellowships to attract highly qualified expatriates back to Denmark.
The claim that over-patenting hinders the development of new treatments is not supported by the evidence, says the US Biotechnology Industry Organization.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.